Litcius/Paper detail

Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping

Patricia Sinclair, Ancha Baranova, Nadine Kabbani

2021Cells22 citationsDOIOpen Access PDF

Abstract

Alzheimer’s disease (AD) is marked by chronic neurodegeneration associated with the occurrence of plaques containing amyloid β (Aβ) proteins in various parts of the human brain. An increase in several Aβ fragments is well documented in patients with AD and anti-amyloid targeting is an emerging area of therapy. Soluble Aβ can bind to various cell surface and intracellular molecules with the pathogenic Aβ42 fragment leading to neurotoxicity. Here we examined the effect of Aβ42 on network adaptations in the proteome of nerve growth factor (NGF) differentiated PC12 cells using liquid-chromatography electrospray ionization mass spectrometry (LC-ESI MS/MS) proteomics. Whole-cell peptide mass fingerprinting was coupled to bioinformatic gene set enrichment analysis (GSEA) in order to identify differentially represented proteins and related gene ontology (GO) pathways within Aβ42 treated cells. Our results underscore a role for Aβ42 in disrupting proteome responses for signaling, bioenergetics, and morphology in mitochondria. These findings highlight the specific components of the mitochondrial response during Aβ42 neurotoxicity and suggest several new biomarkers for detection and surveillance of amyloid disease.

Topics & Concepts

ProteomeNeurodegenerationProteomicsNeurotoxicityAmyloid betaBiologyCell biologyAmyloid precursor proteinAmyloid (mycology)MitochondrionChemistryMolecular biologyAlzheimer's diseaseBiochemistryGenePeptideDiseaseMedicinePathologyOrganic chemistryToxicityBotanyAlzheimer's disease research and treatmentsMitochondrial Function and PathologyBioinformatics and Genomic Networks
Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping | Litcius